Biocon Biologics Secures EC Approval For YESINTEK, Expanding Its European Markets Reach

Biocon Biologics Ltd (BBL), a part of Biocon Ltd, has received marketing approval from the European Commission (EC) for its Ustekinumab biosimilar, YESINTEK. in Europe. This approval enables Biocon to distribute the drug across the European Union (EU), offering an alternative treatment for various inflammatory diseases.

YESINTEK: A New Treatment Option

YESINTEK is a medicine for adults and children with plaque psoriasis and for adults with psoriatic arthritis and Crohn’s disease. Tests have shown that it works just as well and is as safe as the original Ustekinumab drug, making it a good option for patients.

Strengthening Biocon’s Global Position

This milestone reinforces Biocon Biologics’ commitment to providing affordable and high-quality biosimilars worldwide. The company continues to expand its global footprint, leveraging its expertise in biosimilars to improve healthcare accessibility and offer cost-effective treatment options to patients in need.

About Biocon Biologics

Biocon Biologics Ltd is a global company specialising in biosimilars, offering affordable and high-quality medicines for various diseases. As a subsidiary of Biocon Ltd, it focuses on developing and supplying innovative treatments worldwide, improving healthcare access for patients.

Share Performance 

As of February 18, 2025, at 11:10 AM, the shares of Biocon are trading at ₹336.65 per share, down 3.14% from yesterday’s closing price. Over the last month, the stock has declined by 16.16% and over the last year it has fallen by 8.80%. The stock’s 52-week high is ₹404.70 and its low is ₹244.55.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.